IN8bio CMO Trishna Goswami steps down effective Sept 6, 2024

IN8BIO, INC.

Dr. Goswami and company mutually agreed to her departure as Chief Medical Officer.
Separation agreement provides two months' base salary cash severance.
Agreement includes general release, non-disparagement, confidentiality, and cooperation covenants.
Full separation agreement to be filed as exhibit to Q3 2024 10-Q.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Trishna Goswami

Chief Medical Officer

INAB · IN8BIO, INC.

Effective: 2024-09-06
Filed: September 11, 2024, 7:59 PM ET

On September 8, 2024, IN8bio, Inc. (the “Company”) and Trishna Goswami, M.D., the Company’s Chief Medical Officer, reached the mutual decision to have Dr. Goswami step down as Chief Medical Officer, effective September 6, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Trishna Goswami departed as Chief Medical Officer at IN8BIO, INC..

Action: stepped down
Role: Chief Medical Officer

Exact text from the filing

On September 8, 2024, IN8bio, Inc. (the “Company”) and Trishna Goswami, M.D., the Company’s Chief Medical Officer, reached the mutual decision to have Dr. Goswami step down as Chief Medical Officer, effective September 6, 2024.

View on SEC.gov

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-217229

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.